Introduction {#S0001}
============

*Neisseria meningitidis* is a gram negative diplococcus that colonises the human pharyngeal mucosa.^[1](#CIT0001)^ Exposure to *N. meningitidis* is common, with pharyngeal carriage rates of approximately 10% in students aged between 15--19 years in the United Kingdom (UK).^[2](#CIT0002)^ On rare occasions, *N. meningitidis* passes through epithelial cells into the bloodstream causing rapid systemic meningococcal sepsis and potentially meningitis, usually within 10 days of exposure.^[3](#CIT0003)^

In South Australia, there are 2.2 cases of invasive meningococcal disease (IMD) per 100,000 people -- one of the highest notification rates outside of the meningitis belt of sub-Saharan Africa.^[4](#CIT0004),[5](#CIT0005)^ Serogroup B has remained the predominant group causing invasive disease in South Australia over the past decade.^[6](#CIT0006)^ The seasonal trend of invasive meningococcal disease in Australia usually peaks during winter and early spring (June to October).^[7](#CIT0007)^ It is not clear if seasonality impacts on meningococcal carriage prevalence.

In Australia, from 2003 to 2018 a single dose of Meningococcal C containing vaccine (MenCCV) was on the National Immunisation Program for all children at the age of 12 months.^[8](#CIT0008)^ On July 2018 this was replaced by a single dose of MenACWY vaccine. The meningococcal B vaccine (4CMenB) is licensed in Australia but is not funded in the National Immunisation Program. During 2017 and 2018, all year 10, 11, and 12 students in South Australia were offered 4CMenB vaccination as part of a cluster randomised trial to assess the impact of the 4CMenB vaccine on carriage.^[9](#CIT0009)^ Understanding the prevalence of *N. meningitidis* and risk factors for pharyngeal carriage are important precursors to the introduction of meningococcal vaccine programs.^[4](#CIT0004)^ Prevalence of carriage increases in adolescents, peaking at around 19 years of age.^[10](#CIT0010)^ Due to their high prevalence of *N. meningitidis* carriage, adolescents are considered an important group in the transmission of the bacteria. *N. meningitidis* carriage in Australia is poorly understood, primarily due to a dearth of carriage data being available. The only published data available reports a carriage rate of 1.7% from 294 private school boys in Queensland during 1989.^[11](#CIT0011)^

This study preceded and informed methods used in the cluster randomised trial assessing the impact of meningococcal B vaccine (4CMenB) on pharyngeal carriage of *N. meningitidis*. The larger trial is a population-based study involving metropolitan, rural, and remote high school students in South Australia. Over 34,000 students are to be immunised through their school immunisation providers, as well as have oropharyngeal swabs collected over a 3-month period.^[9](#CIT0009)^ Due to vast transport distances in the RCT (up to 1800km), we needed to establish the loss of isolate yield with different times to sample freezing.

New methods for confirmation of *N. meningitidis* carriage are emerging, however the current gold standard remains plating oropharyngeal swabs directly on selective agar culture media.^[12](#CIT0012),[13](#CIT0013)^ Logistically, direct plating of oropharyngeal swabs may not be possible in large population wide interventional vaccine studies.^[13](#CIT0013)^ Inserting swabs into cryopreservative broth and freezing the samples for processing later in batches has been the standard practice in pneumococcal carriage studies, and is now used in some meningococcal carriage studies.^[14](#CIT0014)^ However, the time from swab collection to freezing may be an important factor in the isolation of *Neisseria* species.^[14](#CIT0014)^ Saliva collection has been rarely used in meningococcal carriage studies, although this method is now being used by a group in the UK.^[15](#CIT0015),[16](#CIT0016)^

Our study is the first to estimate carriage prevalence and risk factors of *N. meningitidis* in Australian university students. We sought to identify whether delayed freezing of oropharyngeal samples alters *PorA* PCR positivity, cycle threshold (Ct), or culture positivity of *N. meningitidis*. We also estimated the level of agreement between saliva samples and oropharyngeal swabs in detecting *N. meningitidis* carriage in adolescents, to inform if saliva testing is a useful replacement, or adjunct to oropharyngeal swabs.

Results {#S0002}
=======

421 individual students were enrolled, mean age was 18.5 years (SD 1.4) ([Table 1](#T0001)). There were 259 (61.5%) who returned after 3 months for a second swab (visit 2). A saliva sample was obtained from 239/259 (92.3%) of those that returned for visit 2 ([Figure 1](#F0001)).10.1080/21645515.2018.1551672-T0001Table 1.Characteristics of students at visit 1.Participant characteristics **Age (years): mean (sd)**18.5 (1.4)**Gender: n (%)** Male183 (43.6%)Female237 (56.4%)**Previous verified Men B vaccination: n (%)**6 (1.4%)**Current cold or sore throat: n (%)**54 (12.8%)**Antibiotics: n (%)** Not taken in the past month382 (90.7%)Stopped in the last week8 (1.9%)Stopped in the last month15 (3.6%)YES, currently taking16 (3.8%)**Current smoker: n (%)**8 (1.9%)**E-cigarette use in the last week: n (%)**1 (0.2%)**Water pipe use in the last month: n (%)**14 (3.3%)**Smoker in residence: n (%)** Yes outside56 (13.7%)Yes inside4 (1.0%)**Nights out in a pub/club in the last week: n (%)** 0207 (50.5%)1118 (28.9%)\>285 (20.7%)**Number of people kissed in the last week: n (%)** 0272 (66.8%)1126 (31.0%)\>29 (2.2%)**Current partner: n (%)**115 (28.2%)**Partner smokes: n (%)**5 (4.5%)**Household size: n (%)** \<5 people289 (70.7%)5 to \<10 people104 (25.4%)≥10 people16 (3.9%)**Ethnicity: n (%)** Aboriginal4 (1.0%)Caucasian269 (65.1%)Asian111 (26.9%)Middle East6 (1.5%)African1 (0.2%)Pacific Islander1 (0.2%)Other21 (5.1%) 10.1080/21645515.2018.1551672-F0001Figure 1.Flow-chart of inclusion and follow-up.

Carriage prevalence {#S0002-S2001}
-------------------

Carriage prevalence of all groupable and non-groupable *N. meningitidis* from oropharyngeal swabs detected by *porA* rt-PCR at visit 1 was 6.2% (95% CI, 4.2% to 8.9%). No A, C, or X genogroups were identified ([Table 2](#T0002)). Visit 1 carriage was higher in the students that did not return for their second swab compared to the group that returned ([Table 2](#T0002)). Students who were lost to follow up at visit 2 were significantly more likely to have spent more nights at a pub or club in the week preceding visit 1 than those that were not lost to follow up (p \< 0.001). Other characteristics were similar between participants that were lost to follow up and those that returned (Supplementary table). In participants returning at visit 2 the overall *N. meningitidis* carriage prevalence was 6.2% (95% CI, 3.8% to 9.9%) ([Table 3](#T0003)). Accounting for missing data, the overall carriage prevalence at visit 2 among the 421 students who had a visit 1 oropharyngeal swab was estimated to be 8.6% (95% CI 5.0 to 12.2%). The logistic generalised estimating equation (GEE) found no evidence for a significant difference in the odds of carriage between the two visits (8.6% at visit 2 vs. 6.2% at visit 1, OR 1.42 (95% CI 0.91 to 2.20), p = 0.12). Of the students with swabs at both visits, 7 out of the 10 students who were PCR positive at visit 1 were positive again at visit 2. Three students who were PCR positive at visit 1 were negative at visit 2, all were group Y at visit 1. Nine students who were negative at visit 1 were positive at visit 2, 5 MenY, and 4 non-groupable.10.1080/21645515.2018.1551672-T0002Table 2.Proportion of *Neisseria meningitidis* pharyngeal carriage from oropharyngeal swab, at visit 1 (participants who were lost to follow up), visit 1 (returned for follow up swab), and combined total. Visit 1 swab in those lost to follow up (n = 162)Visit 1 swab in those who returned for visit 2 (n = 259)Visit 1 swab in all participants (n = 421)SerogroupN (%)95% CIN (%)95% CIN (%)95% CI**Group B**4 (2.5%)0.9% to 6.5%3 (1.2%)0.4% to 3.6%7 (1.7%)0.8% to 3.5%**Group W**2 (1.2%)0.3 to 4.9%1 (0.4%)0.05% to 2.7%3 (0.7%)0.2% to 2.2%**Group Y**6 (3.7%)1.7% to 8.1%6 (2.3%)1.0% to 5.1%12 (2.9%)1.6% to 5.0%**Non-groupable**5 (3.1%)1.3% to 7.3%1 (0.4%)0.05% to 2.7%6 (1.4%)0.6% to 3.1%**Total Por A + ve**16\* (9.9%)6.1% to 15.6%10\* (3.9%)2.1% to 7.1%26\*(6.2%)4.2% to 8.9%[^3] 10.1080/21645515.2018.1551672-T0003Table 3.Proportion of *Neisseria meningitidis* carriage at visit 2, in oropharyngeal swab, and saliva sample. Visit 2 swab (n = 259)Visit 2 saliva sample (n = 239)GenogroupN (%)95% CIN (%)95% CI**Group B**3 (1.2%)0.4% to 3.6%3 (1.3%)0.4% to 3.8%**Group W**1 (0.4%)0.1% to 2.7%0 (0%) **Group Y**7 (2.7%)1.3% to 5.6%4 (1.7%)0.6% to 4.4%**Non-groupable**5 (1.9%)0.8% to 4.6%6 (2.5%)1.1% to 5.5%**Total Por A + ve**16 (6.2%)3.8% to 9.9%13 (5.4%)3.2% to 9.2%

There was a moderate level of agreement in the identification of *N. meningitidis* between oropharyngeal swabs and saliva sample collected from participants, Kappa = 0.62 (95% CI, 0.39 to 0.85). Among the subset of 239 participants, saliva collection identified an additional four participants with carriage; one group B, and 3 non-groupable (Supplemental table). These 3 non-groupable samples all had high Ct values (≥37 cycles) and isolates were unable to be cultured for whole genome sequencing, presumably because of very low numbers of organisms present. Of the 9 participants that had *N. meningitidis* detected in both swab and saliva samples, isolates were not recovered from 2 participants, 6 had isolates recovered from both their swab and saliva, and 1 from their swab only. The Ct values from the 9 participants that had *N. meningitidis* detected in both swab and saliva samples were similar (mean 33.3 vs 35.3 cycles, p = 0.30).

Association with *N. meningitidis* carriage {#S0002-S2002}
-------------------------------------------

Attending two or more parties or bars in a week and kissing one or more persons in the last week were associated with increased *N. meningitidis* carriage in univariable analysis ([Table 4](#T0004)). In multivariable analysis, going out to a bar or pub one night a week (OR 4.14 \[95% CI, 1.06 to 16.15\], p = 0.04), two or more nights a week (OR 9.26 \[95% CI, 2.51 to 34.08\], p = 0.001), and one or more persons kissed in the last week (OR 4.13 \[95% CI, 1.63 to 10.45\], p = 0.014) remained statistically significant. The number of participants with carriage (n = 26) was too small to assess an interaction effect between these variables or to include other predictors in the multivariable model.10.1080/21645515.2018.1551672-T0004Table 4.Univariable logistic regression of PCR positive adolescents at visit 1, with participant characteristics.Effect Detected N (%)Odds Ratio (95% CI)P‐value**AgeReference: 17 year olds**5/66 (7.6%)   18 years11/223 (4.9%)0.63 (0.21 to 1.89)0.41 19 years7/67 (10.5%)1.42 (0.43 to 4.73)0.57 \>20 years3/65 (4.6%)0.59 (0.14 to 2.58)0.48**SexReference: Male**14/183 (7.7%)   Female12/237 (5.1%)0.64 (0.29 to 1.42)0.28**Sore throat/ColdReference: No cold**20/367 (5.5%)   Current cold or sore throat6/54 (11.1%)2.17 (0.83 to 5.67)0.11**Antibiotic useReference: No use last month**24/382 (6.3%)   Use in the last month2/39 (5.1%)0.80 (0.18 to 3.55)0.78**SmokerReference: Non-smoker**25/413 (6.1%)   Smoker1/8 (12.5%)2.22 (0.26 to 18.73)0.47**E-cigaretteReference: No E-cig**26/420 (6.2%)   E-cig user0/1 (0%)1 **Water pipe useReference: No use last month**24/407 (5.9%)   Use in the last month2/14 (14.3%)2.66 (0.56 to 12.57)0.22**Resident smokerReference: Non-smoking**24/348 (6.9%)   Smoking residence2/60 (3.3%)0.47 (0.11 to 2.02)0.31**Party, or barReference: None last week**5/207 (2.4%)   One visit in the last week8/118 (6.8%)2.94 (0.94 to 9.20)0.06 Two or more in the last week13/85 (15.3%)7.29 (2.51 to 21.18)\<0.001**Intimate KissingReference: No kissing last week**7/272 (2.6%)   One or more person17/135 (12.6%)5.45 (2.20 to 13.50)\<0.001**PartnerReference: No partner**15/293 (5.1%)   Current partner11/115 (9.6%)1.96 (0.87 to 4.41)0.10**Household sizeReference: \< 5 people**18/289 (6.2%)   \> than 5 people8/120 (6.7%)1.08 (0.45 to 2.54)0.85**MenB vaccinationReference: No prior vaccination**26/413 (6.3%)   Confirmed vaccination0/6 (0%)1 **EthnicityReference: Caucasian**20/269 (7.4%)   Asian3/111 (2.7%)0.36 (0.10 to 1.88)0.09 Other3/33 (9.1%)1.25 (0.35 to 4.44)0.74

*N. meningitidis* identification after freezing at 6, 16, and 48 hours. {#S0002-S2003}
-----------------------------------------------------------------------

Recovery of *N. meningitidis* on selective agar was significantly reduced in the cryovials frozen at 48 hours following collection, compared with those frozen at 6 hours (24/26, 92.3% vs. 14/26, 53.9%, p = 0.002). There was minimal difference between samples frozen at 16 hours compared to 6 hours (24/26, 92.3% vs. 23/26, 88.5%, p = 0.56). *PorA* PCR Ct values in frozen samples were not statistically different when frozen at 6, or 16 hours compared to pre freezing *PorA* PCR. There was a small statistically significant increase in the Ct value at 48 hours compared to baseline (mean 31.9 vs 31.2 cycles, p = 0.01). Little difference was identified in the Ct values at 6 hours compared to baseline (mean 31.0 vs 31.2 cycles, p = 0.51), and 16 hours compared to baseline (mean 31.4 vs 31.2 cycles, p = 0.08).

Genotypic characterization of carriage {#S0002-S2004}
--------------------------------------

From the 55 specimens that were *PorA* PCR positive, *N. meningitidis* was grown from 46 samples. MLST analysis was performed on these isolates. The CC23 clonal complex was most common, followed by CC41/44 ([Table 5](#T0005)). The most common sequence types were ST-23 (CC23 clonal complex) with 8 isolates (17%), followed by ST-1655 (CC23) with 5 isolates (11%), ST-35 (CC35) with 4 isolates (9%). The most common CC41/44 sequence type was ST-44 with 3 isolates (7%). Five of the isolates were non-groupable. There was 1 MenW CC 11 sequence type, and none of the predominant *porA* genotype (P1.7--2,4) that had caused serogroup B disease in South Australia.^[17](#CIT0017)^10.1080/21645515.2018.1551672-T0005Table 5.Genotypic characterization of recovered isolates from throat and saliva samples by meningotype and PubMLST finetyping analysis among participants.Clonal complex (CC)Number of isolates, per swab, saliva and visitMLST (% of isolate)Serogroup(s) (% of isolates)PorA type (% of isolates)FetAfHbpBAST11Swab 1: 2ST-11 (33)W (100)P1.5,2 (100)F1-1 (100)22 (100)2 (100) Swab 2: 1ST-1287 (67)      Saliva: 0      23Swab 1: 7ST-23 (62)Y (100)P1.5--1,10--1 (38)F4-1 (92)25 (100)221 (38) Swab 2: 4ST-1655 (38) P1.5,2 (23)F5--12 (8) 427 (23) Saliva: 2  P1.5--2,10--1 (31)  228 (31)    P1.5--2,10--29 (8)  1212 (8)32Swab 1: 1ST-32 (100)B (100)P1.7,16--26 (100)F3-3 (100)224 (100)U (100) Swab 2: 0       Saliva: 0      35Swab 1: 2ST-35 (100)NG (100)P1.22--1,14 (50)F3-9 (100)16 (100)U (100) Swab 2: 1  P1.18--1 (50)    Saliva: 1      41/44Swab 1: 3ST-44 (50)B (83)P1.18,25--19 (33)F1-5 (83)19 (100)315 (33) Swab 2: 2ST-1097 (17)NG (17)P1.18--1,34 (33)F1-7 (17) U (67) Saliva: 1ST-6058 (17) P1.17--1,1 (17)     ST-13,605 (17) P1.19--1,26--4 (17)   53Swab 1: 0ST-53 (100)cnl (100)P1.7,30--4 (100)F1-2 (100)102 (100)1746 (100) Swab 2: 1       Saliva: 1      167Swab 1: 3ST-167 (25)Y (100)P1.5--1,10--1 (25)F5-2 (25)714 (25)U (25) Swab 2: 1ST-1624 (75) P1.5-1,10--4 (75)F3-4 (75)24 (75)261 (75) Saliva: 0      198Swab 1: 3ST-823cnl (100)P1.17,9 (33)F5-54 (67)U (67) Swab 2: 0(100) P1.18,25 (33)(100)31 (33)1485 (33) Saliva: 0  P1.18,ND (33)   213Swab 1: 1ST-213 (100)B (100)P1.22,14 (100)F5-36 (100)45 (100)U (100) Swab 2: 0       Saliva: 0      1157Swab 1: 0ST-1157 (100)E (100)P1.21--7,16 (100)F5-36 (100)13 (100)U (100) Swab 2: 1       Saliva: 0      4821Swab 1: 1ST-3469 (100)B (100)P1.17--6,23-- 7 (100)F3-36 (100)16 (100)U (100) Swab 2: 1       Saliva: 1      USwab 1: 3ST-13,603 (50)B (50)P1.22,14--6 (50)F1-4 (50)101 (50)1921 (50) Swab 2: 2ST-13,602 (17)cnl (33)P1.19,15 (17)F3-28 (17)25 (17)427 (17) Saliva: 1ST-13,604 (17)Y (17)P1.5,2 (17)F4-1 (17)U (33)U (33)  ST-13,606 (17) P1.ND,ND (17)F2-5 (17)  [^4]

Discussion {#S0003}
==========

Overall rates of carriage of *N. meningitidis* in South Australian university student population were lower than anticipated. This is possibly related to low numbers of participants smoking in this cohort. The numbers of adolescents smoking was lower than rates reported in a 2016 annual survey for 15 to 29 year olds in South Australia of 10.5% (95% CI, 7.8% to 13.2%),^[18](#CIT0018)^ and lower than other recent carriage studies in similar age groups.^[2](#CIT0002),[19](#CIT0019),[20](#CIT0020)^

Some carriage studies have reported a sharp increase in the prevalence of pharyngeal *N. meningitidis* during the first year of university.^[21](#CIT0021),[22](#CIT0022)^ We did not find a statistically significant increase in carriage between the start of university and the visit 2 swab after 3 months. Associations with carriage at visit 1 reflected those reported previously in overseas studies, with attending one or more parties or bars in the last week, and kissing one or more persons in the last week both independently associated with carriage.^[2](#CIT0002),[19](#CIT0019),[20](#CIT0020),[23](#CIT0023)^ Of note, students that went out more than once a week and kissed one or more people had a carriage prevalence of 25%. The low numbers of participants who smoked, used e-cigarettes, or water pipes meant that little can be elucidated from these potential risk factors in this cohort.

Our direct swab PCR method in the pilot study mirrored study processes for a large RCT.^[9](#CIT0009)^ In a UK study of over 2899 sample pairs, the sensitivity and specificity of direct swab *PorA P*CR compared to plating and then PCR of the isolate were 0.66 and 0.99 respectively.^[13](#CIT0013)^ The ability to grow isolates on selective agar were similar at 6 and 16 hours, however there was significant loss (46%) of isolates in samples frozen at 48 hours after collection. This was not reflected in the rt-PCR Ct values at 48 hours, suggesting a loss of viability of the bacteria if left more than 16 hours prior to freezing. Loss of isolates at 6 hours, 16 hours, and even 48 hours were less than previously reported in studies using an alternate transport medium.^[15](#CIT0015)^ STGG transport medium may be the primary reason for increased yields in this study.

Conflicting evidence currently exists regarding the suitability of saliva sampling in *N. meningitidis* carriage studies. Previous saliva methods have differed, with one study obtaining a saliva swab between the lower gums and lips,^[24](#CIT0024)^ and another using gargled 10 ml of sterile phosphate-buffered saline.^[25](#CIT0025)^ Using a swab for saliva collection resulted in overall carriage of 0.4% compared to 32.2% for nasopharyngeal swabs.^[24](#CIT0024)^ Higher detection was reported using mouth gargles, with *N. meningitidis* cultured in 10/89 (11%) compared to 13/89 (15%) in oropharyngeal swabs.^[25](#CIT0025)^ Our results suggest the saliva drool method of collection has the potential to provide a more accurate representation of carriage in adolescents, by increasing sensitivity when combined with oropharyngeal swabs. It does however come with additional costs, laboratory preparation time, and collection time. Saliva testing was of minimal additional value in this study. Higher detection of *N. meningitidis* in saliva than previously reported may have some implication for public health messaging, or contact tracing for the transfer of saliva through drink bottles and eating utensils.

In recent years P1.7--2,4 has been the predominant *PorA* type causing invasive disease in South Australia.^[17](#CIT0017)^ This is closely related to the NZ epidemic strain, but this *PorA* type was not identified from isolates in our pilot study. The majority of serogroup B isolates were comprised of other PorA-type from the CC 41/44, and all CC 23 were serogroup Y. Nevertheless, both CC 41/44 and CC 23 have previously been associated with disease.^[26](#CIT0026),[27](#CIT0027)^ Previous comparisons of invasive disease sequence types to carrier types showed that ST-23 and ST-35 complexes were positively associated with non-invasive carriage.^[28](#CIT0028)^ Both the ST-23 and ST-35 complexes made up the higher proportion of isolates identified in our sample. It is not currently clear what impact the introduction of vaccines will have on inter-strain competition and carriage of non-disease causing meningococci.

The majority of carriage studies performed in university aged adolescents are cross-sectional analyses at a single point in time.^[28](#CIT0028)^ Longitudinal studies are essential for establishing a change in individuals. Longitudinal carriage studies that have been conducted generally report descriptive results of new acquisition, or carriage prevalence at each follow up period.^[13](#CIT0013),[19](#CIT0019),[29](#CIT0029)--[31](#CIT0031)^ Very few have attempted to statistically estimate the difference in carriage over a time period.^[21](#CIT0021)^ To estimate a statistically robust estimate of the difference in carriage prevalence in participants we used GEEs. This approach handles correlated data that arise from repeated measures of the same individuals over time. This approach was also used in a 2014 randomised control trial assessing the impact of MenACWY-CRM and 4CMenB on carriage longitudinally.^[32](#CIT0032)^

The primary motivation for an imputed analysis in this study was to account for differences in risk behaviours between returning students and those lost to follow-up. To illustrate, we found that students who spent one or more nights out at a club or pub in the last week at visit 1 (a) were more likely to be lost to follow-up, and (b) had higher carriage prevalence at both visits. Thus the loss of these students would be expected to lead to an underestimate of the carriage prevalence at visit 2 when restricting the analysis to just those students who returned. In accounting for these differences, the more realistic imputed analysis produces a higher carriage prevalence estimate at visit 2 (8.6%) compared to simply ignoring the missing data and restricting the analysis to returning students (6.2%). If loss to follow-up was related to unmeasured characteristics, and if these unmeasured characteristics were also predictive of carriage, then it is possible that our imputed estimate of carriage will be biased. Given that established predictors of carriage were included in the study questionnaire, however, we believe that the extent of this bias should be reasonably small.

Every effort was made to limit attrition, however in longitudinal adolescent studies this is difficult to control. This is especially so in studies that don't involve a treatment.^[33](#CIT0033)^ Other potential limitations with this study include the generalisability of results, with the low proportion of smokers in the study cohort suggesting an over-representation of health-conscious students. We did not conduct direct plating of oropharyngeal swabs and we compared the recovery of isolates in aliquots frozen at 16 and 48 hours with those frozen at 6 hours. It is possible that direct plating may have identified more meningococcal carriage than the direct swab PCR method and this requires further investigation in regards to isolate loss after freezing.^[13](#CIT0013)^ Regardless of the plating and testing methods used in this study, the sensitivity of swabbing is estimated to be between 60--83%.^[34](#CIT0034)^ The use of a standard operating procedure and training medical and nursing staff in swab technique should have maximised *N. meningitidis* detection.

Due to the carriage prevalence in this age group, adolescents are likely to be an important group to consider if meningococcal vaccines confer herd protection, although the effect of recombinant vaccines on carriage remains inconclusive.^[32](#CIT0032)^ In locations such as South Australia the direct impact of MenB vaccines on reducing invasive disease in adolescents means the introduction of a program is warranted, even without significant herd protection. University students with the highest risk of carriage may be the most likely to benefit from a MenB vaccination program. An adolescent immunisation program conducted in high schools would likely provide the best protection prior to increased mixing and behaviours associated with carriage.

Materials and methods {#S0004}
=====================

Visit 1 {#S0004-S2001}
-------

Recruitment occurred on The University of Adelaide campus during one week prior to commencement (orientation week, 20th to 24th of February 2017). First year university students aged 17 to 25 years were eligible to participate. Approximately 10,000 commencing students enrol at the University of Adelaide each year. Of the total university population, 27% are international students with 49% females and 51% males.^[35](#CIT0035)^ Oropharyngeal swabs from the posterior pharynx using a sweep from one tonsillar area to the other were collected by trained Registered Nurses and Medical Officers using sterile flocked swabs. The swabs were then placed into sterile vials containing 2 mL of skim milk, tryptone, glucose, and glycerol (STGG) transport medium (Thermo Scientific). These samples were kept in a cooler with ice bricks at temperatures between 8 and 14°C for up to 4 hours before being transferred to SA Pathology. A questionnaire adapted from the UK Meningococcal Carriage Group (UKMENCAR4) was completed by students to identify any associations with carriage.^[23](#CIT0023)^ Questions included age, gender, cigarette smoking, e-cigarette use, water pipe use, recent respiratory infection, antibiotic use, attending pubs or clubs, intimate kissing, household size, and ethnicity.

Ethics approval {#S0004-S2002}
---------------

This study was approved by the Women's and Children's Health Network Human Research Ethics Committee (HREC/16/WCHN/140) and all subjects provided written informed consent. Students received a \$20 iTunes voucher on completion of swab collection to reimburse them for their time.

Visit 2 {#S0004-S2003}
-------

Students were contacted via email and telephone to return for a repeat oropharyngeal swab after 3 months. At least three attempts were made to contact students lost to follow up. These visits occurred between 30 May -- 28 August 2017. For those that consented, 1ml of saliva was drooled into an empty sterile container and immediately syringed into a vial containing 1ml of STGG transport media. The oropharyngeal swabs and saliva samples were then stored and tested as described for visit 1.

Laboratory {#S0004-S2004}
----------

On receipt of samples at SA Pathology all specimens were subjected to real-time PCR (rt-PCR) screening for the presence of specific meningococcal DNA using *porA* gene detection prior to freezing. Samples with Ct values ≤40 were considered positive. Further rt-PCR analysis was used on *porA* positive specimens to determine which serogroup was detected (A, B, C, W, X, Y). Non-groupable genotype was defined as no amplification in any serogroup-specific rt-PCR assay. At visit 1, each sample was aliquoted into three cryovials and frozen at −80°C at three different time points (6, 16, and 48 hours) following collection time. No direct plating was performed. Samples were thawed after 2 weeks and prepared for automated extraction on the Roche MagnaPure system. Any samples yielding a *porA* positive rt-PCR prior to freezing were cultured for Neisseria species on selective agar (NIMM, Micro Neisseria Medium (VCTA), BioMerieux Australia) and incubated in CO~2~ at 35°C. Plates were kept for up to 72 hours and examined daily. Potential *Neisseria* species were identified by standard diagnostic laboratory bacteriological methods including oxidase reaction and confirmation of identity using Matrix-assisted laser desorption/ionization time-of-flight mass spectrometer (MALDI ToF). Whole genome sequencing analysis of *N. meningitidis* isolates was also performed. All samples were sequenced on an Illumina NextSeq platform with Illumina NextSeq 500 mid-output (Illumina V2; 2 × 150 cycles) kit, targeting at least 50x genome coverage. Sequencing data were quality filtered using Trimmomatic (v0.36),^[36](#CIT0036)^ and *de novo* assembled using SPAdes (v3.11.1).^[37](#CIT0037)^ Multilocus sequence typing and *N. meningitidis* fine typing were performed using meningotype (v0.8.1-beta),^[38](#CIT0038)^ and on PUBMLST.^[39](#CIT0039)^

Statistical analysis {#S0004-S2005}
--------------------

Using a conservative carriage prevalence estimate of 8% from UK data,^[40](#CIT0040)^ a sample size of 500 university students allowed for the estimation of carriage prevalence ± 2.4%, with precision defined as the half-width of a 95% confidence interval (CI).^[2](#CIT0002)^ In testing for a difference in carriage prevalence between visits, missing data on overall carriage at visit 2 was addressed using multiple imputation (m = 50 imputations). Multiple imputation was performed using chained equations, with a conditional logistic regression model used to impute carriage at visit 2. In addition to carriage at visit 1, additional auxiliary variables (times out at a party, pub, bar or nightclub in the last week and number of people kissed in the last week) were included in this logistic model to help satisfy a missing at random assumption and improve the prediction of missing values. Imputed datasets were analysed using logistic regression models, with generalised estimating equations (GEEs) used to account for repeated measurements within students. To identify risk factors for overall carriage at visit 1, univariable and multivariable logistic regression models were used. A linear mixed effects model was used to investigate if there was a difference in mean Ct values in samples after freezing at 6, 16, and 48 hours. Analyses were completed using Stata v.14.2.
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###### Supplemental Material

[^1]: The protocol for this pilot is published in the Australian New Zealand Clinical Trials Registry ACTRN1261700023332.

[^2]: Color versions of one or more of the figures in the article can be found online at [www.tandfonline.com/khvi](http://www.tandfonline.com/khvi).

[^3]: \* Less than the individual serogroup total because more than one isolate has been detected in two participants (B, Y and W, Y)

[^4]: \*NG -- non-groupable; U -- unknown
